Comparative Effectiveness of Early Natalizumab Treatment in JC Virus-Negative Relapsing-Remitting Multiple Sclerosis
We estimated the long-term risks and benefits of disease modifying therapies. Benefits were favored by natalizumab with minimal increased risks in the negative anti-JC virus population.
Key Considerations for Choosing the Right SMA Treatment
Experts Spotlight Lasting Innovations From the COVID-19 Pandemic
AJMC® in the Press, April 4, 2025
5 Things to Know About Infertility